Everolimus is a potent inhibitor of the growth and proliferation of tumor cells, endothelial cells, fibroblasts, vascular smooth muscle cells, and inhibits glycolysis in solid tumors in vitro and in vivo.

1. The efficacy of everolimus

Kidney cancer: everolimus versus placebo in a multicenter, double-blind, randomized trial in patients with metastatic kidney disease that progressed after prior sorafenib and sunitinib or both Cancer patients showed longer progression-free survival in the everolimus group, with a median progression-free survival of 3 months longer than placebo and more than double that of placebo.

Neuroendocrine tumors: In a multicenter, double-blind, randomized trial of everolimus versus placebo in patients with locally advanced or metastatic advanced pancreatic neuroendocrine tumors (PNETs), there was no Progression survival was longer, with median progression-free survival extending 6.4 months over placebo.

TSC-related SEGA in adults and children: In a double-blind, multicenter trial of everolimus versus placebo in children and adults with TSC-related SEGA, the SEGA response rate was 35% , and 0% for placebo.

Breast cancer: In a double-blind, multicenter trial, everolimus plus exemestane was more effective than placebo plus exemestane in advanced breast cancer, and median progression-free survival was better than placebo extended by 7 months.

2. Precautions for Everolimus

(1) Lung or breathing problems (shortness of breath, chest pain, wheezing)

(2) Infection (fever, chills, rash, joint pain)

(3) Severe allergic reactions (itching, urticaria)

(4) Angioedema (swelling of the mouth, tongue and throat)

(5) Whether the wound can heal normally

(6) Decreased red blood cell, white blood cell and platelet counts (blood tests before and during treatment)

Minkai Bio is committed to providing a variety of high-end generic drugs and innovative drugs. It is a supplier of everolimus, which plays an important role in tumor suppression. Welcome to our website.